Adicet Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $48.68M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | During market hours | – | $-1.99 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | During market hours | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | During market hours | – | $-2.94 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | During market hours | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | During market hours | – | $-0.34 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | During market hours | – | $-0.31 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 6, 2025 | During market hours | – | $-0.32 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | During market hours | – | $-0.34 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | – | $-0.33 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | During market hours | – | $-0.35 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 19, 2024 | During market hours | – | $-0.69 | – |
Press releases
Announcements Adicet Bio filed with the SEC
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
September 28, 2026 Prula-cel Clinical Data Update
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Prula-cel Bar for success to generate transformative market opportunity in patients with SLE with or without lupus nephritis Autoimmune Indications
Regulation FD disclosure · EX-99.1 to Form 8-K
Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Adicet Bio Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
AAV= Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis; IIM= Idiopathic inflammatory myopathy; LN= Lupus nephritis; mCRPC= Metastatic castration-resistant prostate cancer; PSMA= Prostate specific membrane antigen; RA= Rheumatoid arthritis; SLE= Systemic lupus erythematosus; SP…
Other events · EX-99.3 to Form 8-K
Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Adicet Bio Appoints Michael Grissinger to the Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Adicet Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
Regulation FD disclosure · EX-99.1 to Form 8-K
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
Regulation FD disclosure · EX-99.1 to Form 8-K
Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Adicet Bio, Inc. Announces Proposed Public Offering
Material agreement · Results of operations · Other events · EX-99.1 to Form 8-K
Adicet Bio, Inc. Announces Pricing of Public Offering
Material agreement · Results of operations · Other events · EX-99.2 to Form 8-K
Leaders in Developing Allogeneic CAR γδ1 Cell Therapies to Fight Autoimmune Diseases and Cancer January 16, 2024 γδ= Gamma delta; CAR= Chimeric antigen receptor
Regulation FD disclosure · EX-99.1 to Form 8-K
Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K